Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Predicting Outcomes for Patients With Mantle Cell Lymphoma Using Integrative Prognostic Machine Learning Models

08/18/2023

Featuring Holly Hill, PhD

Holly Hill, PhD, shares findings from a study on the value and clinical utility of integrative prognostic machine learning models as a tool for determining accurate predictions of outcomes among patients with MCL.

Holly Hill, PhD, shares findings...

08/18/2023

Oncology

Videos

Promising Prognostic Value of Diagnosis to Treatment Interval Among Patients With Newly Diagnosed Mantle Cell Lymphoma

08/17/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...

Narendranath Epperla, MD, MS, shares findings assessing the potential significance of DTI for predicting outcomes for patients with newly diagnosed MCL.

Narendranath Epperla, MD, MS,...

08/17/2023

Oncology

Videos

BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma

06/27/2023

Featuring Vincent Ribrag, MD

At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.

At the 2023 EHA Congress,...

06/27/2023

Oncology

Videos

Acalabrutinib Combined With Bendamustine and Rituximab for Patients With Treatment-Naive or Relapsed/Refractory MCL

06/26/2023

Featuring Tycel Phillips, MD

Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.

Tycel Phillips, MD, presented...

06/26/2023

Oncology

Videos

Brexucabtagene Autoleucel Treatment for Patients With R/R Mantle Cell Lymphoma: Real-World Outcomes

06/21/2023

Featuring Swetha Kambhampati, MD

Featuring Swetha Kambhampati, MD ...

At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Videos

Evaluating BCL6-Positive and CD10-Positive Expression for Mantle Cell Lymphoma Treatment and Management

06/14/2023

Featuring Won Jin Jeon, MD

At the 2023 ASCO annual meeting, Won Jin Jeon, MD, presented data from a meta-analysis that explored the prognostic value of identifying BCL6 and CD10 variants in the treatment and management of mantle cell lymphoma.

At the 2023 ASCO annual meeting,...

06/14/2023

Oncology

Videos

Adding Ibrutinib to Induction or Maintenance With or Without AutoHSCT Shows Strong Efficacy, Acceptable Toxicity in MCL

12/21/2022

Martin Dreyling, MD, discusses data from the Triangle trial showing strong efficacy and acceptable safety with the addition of ibrutinib to induction or maintenance treatment with or without autoHSCT in younger patients with MCL.

Martin Dreyling, MD, discusses...

12/21/2022

Oncology

Videos

Treatment Approaches for Patients With Untreated and Relapsed MCL

05/23/2022

Tycel Phillips, MD, reviews standard therapies utilized for patients with MCL, including nonaggressive regimens and BTK inhibitor therapies.

Tycel Phillips, MD, reviews...

05/23/2022

Oncology

Preetesh Jain, MD, PhD, University of Texas MD Anderson Cancer Center

Videos

Ibrutinib Plus Rituximab Demonstrates Promising Efficacy in Older Patients With Previously Untreated MCL

05/15/2022

Preetesh Jain, MD, discusses results from a phase 2 trial exploring the efficacy and safety of ibrutinib plus rituximab for the first-line treatment of older patients with MCL.

Preetesh Jain, MD, discusses...

05/15/2022

Oncology

Videos

3D Cultivation Improves Survival Time of Primary Mantle Cell Lymphoma Cells, Enables Long-term Experiments

04/30/2022

Kathrin Böpple, PhD, and Meng Dong, PhD discuss the development of a 3D cultivation system with alginate hydrogel that improves the in vitro survival time of primary mantle cell lymphoma cells.

Kathrin Böpple, PhD, and Meng...

04/30/2022

Oncology

Recent News

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...

According to interim analysis...

04/25/2024

Oncology

News

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

04/25/2024

Stephanie Holland

Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...

Based on results from the...

04/25/2024

Oncology

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Based on results from the...

04/24/2024

Oncology

News

Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma

04/23/2024

Stephanie Holland

Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...

Results from the phase 2 NRG...

04/23/2024

Oncology

News

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

News

FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/19/2024

Stephanie Holland

Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.

Based on results from the phase...

04/19/2024

Oncology

News

IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization

04/19/2024

Amber Denham

According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...

According to phase 2 results,...

04/19/2024

Oncology